A phase II study of anlotinib and an anti-PDL1 antibody in patients with alveolar soft part sarcoma: Results of expansion cohorts.

作者
Zhichao Tan,Yan Zhao Wu,Zhengfu Fan,Jiayong Liu,Tian Gao,Chujie Bai,Ruifeng Xue,Shu Li,Lu Zhang,Xinyu Wang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (16_suppl): 11515-11515 被引量:4
标识
DOI:10.1200/jco.2024.42.16_suppl.11515
摘要

11515 Background: The combination of the anti-angiogenesis tyrosine kinase inhibitor (TKI), anlotinib, with the anti-programmed death-ligand 1 (PDL1) antibody (TQB2450) demonstrated commendable antitumor efficacy in a phase II clinical trial for pan-sarcoma patients, particularly within the alveolar soft part sarcoma (ASPS) cohorts (Liu et al., 2022, PMID: 35675031). An expansion of the ASPS cohort has been underway since 2019. Herein, we present the observed efficacy within this ASPS-specific expansion cohort. Methods: ASPS patients naïve to TKIs or immunotherapy received TQB2450 (1200mg) intravenously on day 1, in combination with oral administration of anlotinib (12mg) from day 1 to 14, repeated every 3 weeks. The primary endpoint was best objective response rate (ORR, per RECIST v1.1). Secondary endpoints comprised median progression free survival (PFS), median overall survival (OS), duration of response (DOR), and adverse events (AEs). Formalin-fixed paraffin-embedded (FFPE) slides were taken for immunohistochemistry and examined for lymphocyte marker expression. Results: Twenty-nine patients were enrolled in the phase II trial. The median age was 29 years (range: 19-46), with female 48.3%. A subset of patients (20.7%) had undergone prior lines of chemotherapy. Twenty-eight patients were evaluable for efficacy (one withdrew). The ORR for evaluable patients reached 79.3%, characterized by 3 complete responses and 20 partial responses. The median PFS (months) was not reached (95%CI: 20.7, not-reached). The median DOR (months) for responders was not reached (95%CI: 18.0, not-reached). No mortalities occurred during the follow-up. Treatment demonstrated favorable tolerability, with predominant grade 1 and 2 AEs. Thirteen patients (44.83%) experienced grade ≥3 AEs, principally hypertriglyceridemia (13.79%), lipase elevation (6.90%), amylase elevation (3.45%), and hypertension (3.45%). A detailed analysis of the tumor microenvironment in 7 patients, including 3 good responders and 4 poor responders, revealed a significant discrepancy in the presence of tertiary lymphoid structures (TLS) between the two groups (refer to Table). Conclusions: The combination of anlotinib and TQB2450 exhibits promising efficacy in ASPS patients, markedly enhancing ORR and extending PFS with favorable tolerability. Notably, TLS emerges as a potential predictive indicator of immunotherapeutic efficacy in ASPS. Clinical trial information: CTR20190938 . [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
完美世界的应助被lnx采纳,获得30
1秒前
稳重听双发布了新的文献求助10
1秒前
1秒前
魔幻傲儿完成签到,获得积分10
1秒前
Lucas的应助被mont采纳,获得20
2秒前
XHY完成签到,获得积分10
3秒前
4秒前
zzq发布了新的文献求助10
4秒前
曾经冰露完成签到,获得积分10
5秒前
5秒前
小宋完成签到,获得积分10
5秒前
5秒前
5秒前
斯文败类的应助被符聪采纳,获得10
6秒前
杳杳完成签到 ,获得积分10
6秒前
娇娇发布了新的文献求助10
6秒前
淡淡的萱萱完成签到,获得积分10
6秒前
Gemlabmem发布了新的文献求助10
6秒前
daxiong完成签到,获得积分10
7秒前
7秒前
斯文败类的应助被酸酸采纳,获得10
7秒前
冷茗发布了新的文献求助10
7秒前
科研通AI6.4的应助被yumi采纳,获得10
7秒前
孤独觅山完成签到,获得积分20
8秒前
打打的应助被晨煜采纳,获得10
8秒前
CipherSage的应助被积极努力采纳,获得30
8秒前
bcc发布了新的文献求助10
8秒前
Ava的应助被金秋采纳,获得10
8秒前
博修发布了新的文献求助100
8秒前
bkagyin的应助被典雅的寄真采纳,获得10
9秒前
JOJO发布了新的文献求助10
10秒前
科研努力发布了新的文献求助10
10秒前
10秒前
syvshc的应助被绪安然采纳,获得10
10秒前
10秒前
Ava的应助被科研通管家采纳,获得20
10秒前
传奇3的应助被科研通管家采纳,获得10
11秒前
11秒前
隐形伯云的应助被科研通管家采纳,获得10
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175707
求助须知:如何正确求助?哪些是违规求助? 9567353
关于积分的说明 21792214
捐赠科研通 7770334
什么是DOI,文献DOI怎么找? 3431908
关于科研通互助平台的介绍 2556260
邀请新用户注册赠送积分活动 2477417